Integrated Blood Pressure Control
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals
(5508) Total Article Views
Authors: Cheryl L Laffer, Fernando Elijovich
Published Date January 2011
Volume 2011:4 Pages 1 - 5
Cheryl L Laffer1, Fernando Elijovich2
1Section of Hypertension and Vascular Medicine, 2Division of General Internal Medicine, Department of Medicine, Texas A&M Health Sciences Center College of Medicine, Temple, TX USA
Abstract: Recent guidelines for the treatment of hypertension have focused on the need for multiple medications to get most patients to goal blood pressure (BP). Two to three different classes of antihypertensive agents are frequently required, increasing the risk of poor compliance with therapy. Hence, the guidelines have recommended starting with combination therapy in patients with BP that is over 20 mm Hg systolic or 10 mm Hg diastolic above goal. The latest advance in treatment regimen has been the development of triple-therapy combinations of an angiotensin receptor blocker, amlodipine, and hydrochlorothiazide. We review the pathophysiologic rationale for such a combination and the efficacy, safety, and tolerability of the first triple therapy that has become available: valsartan + amlodipine + hydrochlorothiazide. Finally, we suggest that use of triple therapy could improve the accuracy of diagnosing resistant hypertension, an increasingly prevalent and severe condition, by enhancing adherence to treatment and weeding out patients with pseudoresistance. This would allow for implementation of expensive and invasive workup only in those truly resistant patients in whom it is justified.
Keywords: combination therapy, compliance, hypertension control rates, resistant hypertension
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- The western diet and lifestyle and diseases of civilization
- Everolimus-eluting stents in interventional cardiology
- Transitioning from population to individualized preventive cardiology